Società Italiana per lo Studio dell'Emostasi e della Trombosi


 Recommendation on the Nomenclature for

Oral Anticoagulants

On behalf of the Control of Anticoagulation Subcommittee of

the SSC of the ISTH

Geoffrey D Barnes, Walter Ageno, Jack Ansell, Scott Kaatz


Scope and methodology Oral anticoagulants are used to prevent and treat a wide range of thromboembolic diseases.

Currently available oral anticoagulants include the vitamin K antagonists (VKA), such as warfarin. VKAs reduce the synthesis of functional vitamin K-dependent factors (II, VII, IX, X as well as protein C and protein S) by interfering in the vitamin K redox cycle.

The newer oral anticoagulants (dabigatran, rivaroxaban, apixaban, edoxaban and betrixaban) each directly inhibit an activated clotting factor, either IIa or Xa.

Their pharmacokinetic and pharmacodynamic properties are more predictable than the VKAs and therefore do not require routine monitoring of anticoagulant effect.[1]